Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi-Center Retrospective Cohort.
코호트
2/5 보강
OpenAlex 토픽 ·
Thyroid Cancer Diagnosis and Treatment
Brain Metastases and Treatment
Lung Cancer Research Studies
[BACKGROUND] Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis.
- 표본수 (n) 9
- p-value p = 0.03
- p-value p = 0.0001
APA
Liyona Kampel, Shaun Edalati, et al. (2026). Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi-Center Retrospective Cohort.. Head & neck, 48(5), 1332-1339. https://doi.org/10.1002/hed.70139
MLA
Liyona Kampel, et al.. "Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi-Center Retrospective Cohort.." Head & neck, vol. 48, no. 5, 2026, pp. 1332-1339.
PMID
41416947 ↗
Abstract 한글 요약
[BACKGROUND] Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes.
[METHODS] A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features, histopathology, treatments, and survival data were collected.
[RESULTS] Twenty patients were identified: 11 (55%) had papillary thyroid carcinoma, 8 (40%) had follicular carcinoma and 1 had Hurtle cell carcinoma. BM treatments included neurosurgical resection (n = 9), stereotactic radiosurgery (n = 14), and whole-brain radiotherapy (n = 6). Median survival following BM diagnosis was 16.2 months. Patients who did not undergo surgical resection had significantly shorter survival than those whose BM were resected (13 vs. 80 months, p = 0.03). Survival was also worse among patients receiving systemic therapy at the time BM developed (8.9 vs. 80 months, p = 0.0001).
[CONCLUSION] Unresected BM of DTC and those arising during systemic therapy portend high mortality.
[METHODS] A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features, histopathology, treatments, and survival data were collected.
[RESULTS] Twenty patients were identified: 11 (55%) had papillary thyroid carcinoma, 8 (40%) had follicular carcinoma and 1 had Hurtle cell carcinoma. BM treatments included neurosurgical resection (n = 9), stereotactic radiosurgery (n = 14), and whole-brain radiotherapy (n = 6). Median survival following BM diagnosis was 16.2 months. Patients who did not undergo surgical resection had significantly shorter survival than those whose BM were resected (13 vs. 80 months, p = 0.03). Survival was also worse among patients receiving systemic therapy at the time BM developed (8.9 vs. 80 months, p = 0.0001).
[CONCLUSION] Unresected BM of DTC and those arising during systemic therapy portend high mortality.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.